GCC's roughly 140,000 Saudi Arabia SCD patients depend on a 25-year-old generic after both novel disease-modifiers hit regulatory trouble since 2023.

GCC carries an estimated 200,000-250,000 sickle cell disease patients, with Saudi Arabia alone accounting for roughly 140,000, among the highest national disease burdens outside sub-Saharan Africa. Carrier frequency reaches 6-7% in Saudi Arabia's Eastern Province and 10-15% in Bahrain and Oman. National premarital screening programmes operate in Saudi Arabia, the UAE, Qatar, and Bahrain, and are measurably reshaping epidemiology: carrier-carrier marriages are declining 15-20% annually in Saudi Arabia. Hydroxyurea, generic since 1998, remains the region's only disease-modifying therapy with a stable market position, prescribed to an estimated 35-40% of eligible patients, a higher rate than the US's 25-30%.

Both novel disease-modifying agents that reached GCC registration have since encountered regulatory setbacks. Crizanlizumab (Adakveo), SFDA-registered in 2021, was withdrawn from the EU market in 2023 after its confirmatory trial failed, leaving its GCC formulary position under MOH review. Voxelotor (Oxbryta) was voluntarily withdrawn by the FDA in 2024 for the same reason, and most GCC centres are now transitioning patients off it. Gene therapies Casgevy and Lyfgenia, FDA- and EMA-approved in December 2023, are not yet SFDA- or MOHAP-registered as of mid-2024, though KFSH&RC and SKMC are building cell-therapy capability that could accommodate them by 2025-2026.

Two novel disease-modifiers failed just as gene therapy access remains 18-24 months away.

Five questions this report answers:

Q1 - What is the current MOH/SFDA formulary status of crizanlizumab and voxelotor after their withdrawals?

Q2 - When are Casgevy and Lyfgenia likely to reach SFDA/MOHAP registration in the GCC?

Q3 - How are national premarital screening programmes changing the SCD patient pipeline in KSA, UAE, Qatar, and Bahrain?

Q4 - Why have both novel SCD disease-modifying agents run into regulatory trouble since 2023?

Q5 - Which GCC centres are building the cell-therapy infrastructure to deliver Casgevy and Lyfgenia?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#SickleCellDisease #GCC #GeneTherapy #RareDisease #Hydroxyurea #MarketAccess

Live report page:  https://axlrx.ai/sickle-cell-disease/gcc/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/